Form 483

Cipla Limited Form 483, 2017-06-23

FDA issued a Form 483 to Cipla Limited on 2017-06-23 with 18 public-safe observations.

483· Form 483 issuedHuman Drugs18 observations

Cipla Limited · Pithampur, District Dhar, India · Issued June 23, 2017

Overview

  • 18 public-safe observations are available for this inspection.
  • 6 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

23 Jun 2017
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Doan T Nguyen

23 Jun 2017
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Doan T Nguyen

23 Jun 2017
21 CFR 211.160(b)(3)

Drug product sample

Cited by Doan T Nguyen

23 Jun 2017
21 CFR 211.160(b)(3)

Drug product sample

Cited by Doan T Nguyen

23 Jun 2017
21 CFR 211.165(d)

Acceptance criteria for sampling & testing

Cited by Doan T Nguyen

Inspected site

CLCipla LimitedPithampur, District Dhar, India

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations3x
21 CFR 211.160(b)(3)Cited across public-safe Form 483 observations3x
21 CFR 211.165(d)Cited across public-safe Form 483 observations3x
21 CFR 211.192Cited across public-safe Form 483 observations3x
21 CFR 211.25(a)Cited across public-safe Form 483 observations3x
21 CFR 211.87Cited across public-safe Form 483 observations3x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 18 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere